@medicinegov Medlearn (@medicinegov) 's Twitter Profile
@medicinegov Medlearn

@medicinegov

Videos and virtual events for the NHS | @MedicineGov | #MedLearn #MedLearn24 #Cancer #Oncology #NHS

ID: 3311856665

linkhttps://www.youtube.com/@MedicineGov/featured calendar_today07-06-2015 12:59:09

78,78K Tweet

5,5K Takipçi

23 Takip Edilen

@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors’ Wellbeing, the ESMO Congress 2024 Takes a Holistic View of Oncology esmo.org/esmo/newsroom/… 📢 ESMO - Eur. Oncology #MedicalOncology #CancerNews #Oncology #Cancer

From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors’ Wellbeing, the ESMO Congress 2024 Takes a Holistic View of Oncology esmo.org/esmo/newsroom/… 📢 <a href="/myESMO/">ESMO - Eur. Oncology</a> #MedicalOncology #CancerNews #Oncology #Cancer
@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group of Women with Early-Stage Disease esmo.org/esmo/newsroom/… 📢 ESMO - Eur. Oncology #MedicalOncology #CancerNews #Oncology #Cancer

Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group of Women with Early-Stage Disease esmo.org/esmo/newsroom/… 📢 <a href="/myESMO/">ESMO - Eur. Oncology</a> #MedicalOncology #CancerNews #Oncology #Cancer
@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

The five most common types of#BloodCancer: Acute myeloid leukaemia #AML Chronic lymphocytic leukaemia #CLL Chronic myeloproliferative neoplasms #MPN Diffuse large B-cell lymphoma #DLBCL Myeloma Blood Cancer UK #BloodCancerAwareness #NHS #Cancer #oncology #MedLearn24 #LooksLikeMe

The five most common types of#BloodCancer:
Acute myeloid leukaemia #AML
Chronic lymphocytic leukaemia #CLL
Chronic myeloproliferative neoplasms #MPN
Diffuse large B-cell lymphoma #DLBCL
Myeloma

<a href="/bloodcancer_uk/">Blood Cancer UK</a>
#BloodCancerAwareness #NHS #Cancer #oncology
#MedLearn24 #LooksLikeMe
@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

Transform the diagnosis, treatment and care for cancer patients in England 👉 #MedLearn24 🌐 medicinegov.org #NHS #Cancer #Oncology

@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

#Belzutifan - First ever drug approved for NHS patients with life-threatening genetic, tumour-causing disease 💙 NHS England #NHSnews #NHS england.nhs.uk/2024/09/first-…

@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

Comparing long-term efficacy and safety of GP versus TPF sequential chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis bmccancer.biomedcentral.com/articles/10.11… 🧪 BMC #CancerResearch

Comparing long-term efficacy and safety of GP versus TPF sequential chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis bmccancer.biomedcentral.com/articles/10.11… 🧪 <a href="/BioMedCentral/">BMC</a> #CancerResearch
@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

Exosomal transcript cargo and functional correlation with HNSCC patients’ survival bmccancer.biomedcentral.com/articles/10.11… 🧪 BMC #CancerResearch

Exosomal transcript cargo and functional correlation with HNSCC patients’ survival bmccancer.biomedcentral.com/articles/10.11… 🧪 <a href="/BioMedCentral/">BMC</a> #CancerResearch
@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer bmccancer.biomedcentral.com/articles/10.11… 🧪 BMC #CancerResearch

A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer bmccancer.biomedcentral.com/articles/10.11… 🧪 <a href="/BioMedCentral/">BMC</a> #CancerResearch
@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

📢 Seeking Asian language resources on #Chemotherapy #Radiotherapy #NHSCancer #PatientEducation. Let's avoid reinventing the wheel 🛞 share your materials, and we'll help distribute them #NHSInterpreting #MedicalInterpreting #LooksLikeMe #Interpreting #Translation #Cancer #OncEd

📢 Seeking Asian language resources on #Chemotherapy #Radiotherapy #NHSCancer #PatientEducation. Let's avoid reinventing the wheel 🛞 share your materials, and we'll help distribute them

#NHSInterpreting #MedicalInterpreting #LooksLikeMe
#Interpreting #Translation #Cancer #OncEd
@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

How to get your video featured and promoted in #MedLearn24 for ⭐️FREE | If you want to know how it works and how we can help you promote your work, schedule a brief call here: meetings.hubspot.com/medlearn/disco… #NHSsm #NHScomms #Cancer #Oncology #NHS #CharityComms

@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

A causal relationship between bone mineral density and breast cancer risk: a mendelian randomization study based on east Asian population bmccancer.biomedcentral.com/articles/10.11… 🧪 BMC #CancerResearch

A causal relationship between bone mineral density and breast cancer risk: a mendelian randomization study based on east Asian population bmccancer.biomedcentral.com/articles/10.11… 🧪 <a href="/BioMedCentral/">BMC</a> #CancerResearch
@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

Central nervous system pediatric multi-disciplinary tumor board: a single center experience bmccancer.biomedcentral.com/articles/10.11… 🧪 BMC #CancerResearch

Central nervous system pediatric multi-disciplinary tumor board: a single center experience bmccancer.biomedcentral.com/articles/10.11… 🧪 <a href="/BioMedCentral/">BMC</a> #CancerResearch
@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

Studies Show Immunotherapy Improves Long-Term Survival in Growing Number of Cancers esmo.org/esmo/newsroom/… 📢 ESMO - Eur. Oncology #MedicalOncology #CancerNews #Oncology #Cancer

Studies Show Immunotherapy Improves Long-Term Survival in Growing Number of Cancers esmo.org/esmo/newsroom/… 📢 <a href="/myESMO/">ESMO - Eur. Oncology</a> #MedicalOncology #CancerNews #Oncology #Cancer
@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

Tune into the most comprehensive NHS-focused YouTube channel available. There's something for everyone on the MedicineGov YouTube channel. Take a look at the Playlists and let us know if you have a video you'd like to be added to them #NHS VIEW: youtube.com/@MedicineGov/f…

@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

🌍 Learn how to bridge gaps in cancer care provision. Get the full program now! #CancerEquity 🌐 medicinegov.org #MedLearn24 #Cancer #NHS

🌍 Learn how to bridge gaps in cancer care provision. Get the full program now! #CancerEquity 🌐 medicinegov.org  #MedLearn24 #Cancer #NHS
@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

Sex disparity, prediagnosis lifestyle factors, and long-term survival of gastric cancer: a multi-center cohort study from China bmccancer.biomedcentral.com/articles/10.11… 🧪 BMC #CancerResearch

Sex disparity, prediagnosis lifestyle factors, and long-term survival of gastric cancer: a multi-center cohort study from China bmccancer.biomedcentral.com/articles/10.11… 🧪 <a href="/BioMedCentral/">BMC</a> #CancerResearch
@medicinegov Medlearn (@medicinegov) 's Twitter Profile Photo

Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in Cisplatin-Ineligible Patients with mUC Progressing to Previous Treatment with ICI esmo.org/esmo/oncology-… 📢 ESMO - Eur. Oncology #MedicalOncology #CancerNews #Oncology #Cancer

Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in Cisplatin-Ineligible Patients with mUC Progressing to Previous Treatment with ICI esmo.org/esmo/oncology-… 📢 <a href="/myESMO/">ESMO - Eur. Oncology</a> #MedicalOncology #CancerNews #Oncology #Cancer